株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界における経肺ドラッグデリバリーシステム市場

Global Pulmonary Drug Delivery Systems Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 276794
出版日 ページ情報 英文 118 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
世界における経肺ドラッグデリバリーシステム市場 Global Pulmonary Drug Delivery Systems Market 2015-2019
出版日: 2014年11月19日 ページ情報: 英文 118 Pages
概要

2014年から2019年の世界における経肺ドラッグデリバリーシステム市場の複合年間成長率(CAGR)は、8.90%が見込まれています。

当レポートでは、南北アメリカ、EMEA(欧州・中東・アフリカ地域)、アジア太平洋地域における経肺ドラッグデリバリーシステム市場の現況とその将来予測、主要ベンダーの分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 製品タイプ別の市場分類

第8章 定量噴霧吸入器(MDI)

  • イントロダクション
  • 主要コンポーネント
  • 薬剤沈着
  • 利点と欠点
  • 市場規模と予測

第9章 ドライパウダー吸入器(DPI)

  • イントロダクション
  • 分類
  • 主要コンポーネント
  • ドラッグデリバリー
  • 薬剤沈着
  • 利点と欠点
  • 市場規模と予測

第10章 ネブライザー

  • イントロダクション
  • 利点と欠点
  • 分類
  • ジェットネブライザー
  • 超音波ネブライザー
  • 市場規模と予測

第11章 地理区分

  • 南北アメリカの経肺ドラッグデリバリーシステム市場
  • 欧州・中東・アフリカ地域の経肺ドラッグデリバリーシステム市場
  • アジア太平洋地域の経肺ドラッグデリバリーシステム市場

第12章 購入基準

第13章 市場成長因子

第14章 成長因子とその影響

第15章 市場の課題

第16章 成長因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • AstraZeneca
    • Boehringer Ingelheim
    • GlaxoSmithKline
    • Novartis
    • Philips Healthcare
  • その他の有力ベンダー

第20章 主要ベンダーの分析

  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Philips Healthcare

第21章 関連レポート

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR4715

About Pulmonary Drug Delivery Systems

Pulmonary delivery of drugs leads to the deposition of drugs in the lungs and subsequent local or systemic therapeutic activity. The pulmonary route of administration for the non-invasive delivery of drugs is mostly preferred because of the large surface area for absorption, high blood circulation, and high permeability rate. Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity. Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices such as MDIs (or pMDIs), PDIs, and nebulizers. Drugs administered by this route are deposited in the respiratory tract via inertial impaction, gravitational sedimentation, and diffusion. The effective delivery of drugs via the pulmonary route requires an optimized combination of drug, its formulation, and device.

TechNavio's analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 8.90 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Pulmonary Drug Delivery Systems market for the period 2015-2019. To calculate the market size, the report considers the revenue from the sales of various pulmonary drug delivery systems intended for oral inhalation including:

  • MDIs (or pMDIs)
  • DPIs
  • Nebulizers

TechNavio's report, the Global Pulmonary Drug Delivery Systems Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Pulmonary Drug Delivery Systems market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Philips Healthcare

Other Prominent Vendors

  • 3M Health Care
  • Actelion Pharmaceuticals
  • Aerogen
  • Airon
  • Allied Healthcare Products
  • Briggs Healthcare
  • Carefusion
  • Clement Clarke International
  • DeVilbiss Healthcare
  • Drive Medical Design and Manufacturing
  • GF Health Products
  • Heyer Medical
  • OMRON
  • PARI Medical Holding
  • Salter Labs
  • Teleflex

Market Driver

  • Increase in Prevalence and Incidence of Respiratory Diseases
  • For a full, detailed list, view our report

Market Challenge

  • Intense Market Competition
  • For a full, detailed list, view our report

Market Trend

  • Increase in Online Marketing Services
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Product Type

08. MDIs

  • 08.1. Introduction
  • 08.2. Basic Components
  • 08.3. Drug Deposition
  • 08.4. Pros and Cons of MDIs
  • 08.5. Market Size and Forecast

09. DPIs

  • 09.1. Introduction
  • 09.2. Segmentation
  • 09.3. Basic Components
  • 09.4. Drug Delivery
  • 09.5. Drug Deposition
  • 09.6. Pros and Cons of DPIs
  • 09.7. Market Size and Forecast

10. Nebulizers

  • 10.1. Introduction
  • 10.2. Pros and Cons of Nebulizers
  • 10.3. Segmentation
  • 10.4. Jet Nebulizers
  • 10.5. Ultrasonic Nebulizers
  • 10.6. Market Size and Forecast

11. Geographical Segmentation

  • 11.1. Pulmonary Drug Delivery Systems Market in Americas
    • 11.1.1. Market Size and Forecast
  • 11.2. Pulmonary Drug Delivery Systems Market in EMEA Region
    • 11.2.1. Market Size and Forecast
  • 11.3. Pulmonary Drug Delivery Systems Market in APAC Region
    • 11.3.1. Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. AstraZeneca
    • 19.2.2. Boehringer Ingelheim
    • 19.2.3. GlaxoSmithKline
    • 19.2.4. Novartis
    • 19.2.5. Philips Healthcare
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. AstraZeneca plc
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation by Revenue 2013
    • 20.1.4. Business Segmentation by Revenue 2011-2013
    • 20.1.5. Sales by Geography
    • 20.1.6. Business Strategy
    • 20.1.7. Key Developments
    • 20.1.8. SWOT Analysis
  • 20.2. Boehringer Ingelheim
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation by Revenue 2013
    • 20.2.4. Business Segmentation by Revenue 2012 and 2013
    • 20.2.5. Geographical Segmentation by Revenue 2013
    • 20.2.6. Business Strategy
    • 20.2.7. Recent Developments
    • 20.2.8. SWOT Analysis
  • 20.3. GlaxoSmithKline
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation
    • 20.3.4. Business Segmentation by Revenue 2012 and 2013
    • 20.3.5. Sales by Geography
    • 20.3.6. Pipeline Products
    • 20.3.7. Business Strategy
    • 20.3.8. Key Information
    • 20.3.9. SWOT Analysis
  • 20.4. Novartis
    • 20.4.1. Key Facts
    • 20.4.2. Business Description
    • 20.4.3. Business Segmentation
    • 20.4.4. Revenue by Business Segmentation
    • 20.4.5. Revenue Comparison 2012 and 2013
    • 20.4.6. Sales by Geography
    • 20.4.7. Business Strategy
    • 20.4.8. Key Developments
    • 20.4.9. SWOT Analysis
  • 20.5. Philips Healthcare
    • 20.5.1. Key Facts
    • 20.5.2. Business Overview
    • 20.5.3. Revenue by Business Segmentation 2012
    • 20.5.4. Sales by Geography
    • 20.5.5. Business Strategy
    • 20.5.6. Key Developments
    • 20.5.7. SWOT Analysis

21. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Pulmonary Drug Delivery Systems Market 2014-2019 (US$ billion)
  • Exhibit 3: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type
  • Exhibit 4: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2014
  • Exhibit 5: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2019
  • Exhibit 6: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2014-2019 (US$ billion)
  • Exhibit 7: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2014-2019
  • Exhibit 8: YoY Growth Rate of Global Pulmonary Drug Delivery Systems Market by Product Type 2014-2019
  • Exhibit 9: Revenue and CAGR of Global Pulmonary Drug Delivery Systems Market by Product Type 2014-2019
  • Exhibit 10: Metered Dose Inhaler
  • Exhibit 11: Pros and Cons of MDIs
  • Exhibit 12: Global MDIs Market 2014-2019 (US$ billion)
  • Exhibit 13: DPIs Segmentation by Product Type
  • Exhibit 14: Pros and Cons of DPIs
  • Exhibit 15: Global DPIs Market 2014-2019 (US$ billion)
  • Exhibit 16: Pros and Cons of Nebulizers
  • Exhibit 17: Nebulizers by Product Type
  • Exhibit 18: Jet Nebulizer
  • Exhibit 19: Ultrasonic Nebulizer
  • Exhibit 20: Global Nebulizers Market 2014-2019 (US$ billion)
  • Exhibit 21: Global Pulmonary Drug Delivery Systems Market Segmentation by Geography 2014
  • Exhibit 22: Global Pulmonary Drug Delivery Systems Market Segmentation by Geography 2019
  • Exhibit 23: Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019 (US$ billion)
  • Exhibit 24: Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019
  • Exhibit 25: YoY Growth Rate of Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019
  • Exhibit 26: Revenue and CAGR of Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019
  • Exhibit 27: Percentage Share of Global Pulmonary Drug Delivery Systems Market by Geography 2014 and 2019
  • Exhibit 28: Pulmonary Drug Delivery Systems Market in the Americas 2014-2019 (US$ billion)
  • Exhibit 29: Pulmonary Drug Delivery Systems Market in the EMEA Region 2014-2019 (US$ billion)
  • Exhibit 30: Pulmonary Drug Delivery Systems Market in EMEA Region by Geography 2014
  • Exhibit 31: Pulmonary Drug Delivery Systems Market in the APAC Region 2014-2019 (US$ billion)
  • Exhibit 32: Pulmonary Drug Delivery Systems Market in APAC Region by Geography 2014
  • Exhibit 33: Pulmicort Sales 2011-2014 (US$ million)
  • Exhibit 34: Parts of Pulmicort Flexhaler
  • Exhibit 35: Pulmicort Sales by Geography H1 2014
  • Exhibit 36: Symbicort Sales 2011-2014 (US$ million)
  • Exhibit 37: Symbicort Sales by Geography H1 2014
  • Exhibit 38: Respimat Soft Mist Inhaler
  • Exhibit 39: Spiriva HandiHaler
  • Exhibit 40: Parts of Spiriva HandiHaler
  • Exhibit 41: Spiriva Respimat Cartridge and Parts of Spiriva Respimat Inhaler
  • Exhibit 42: Spiriva Sales 2011-2014 (US$ million)
  • Exhibit 43: Combivent Respimat Catridge and Parts of Combivent Respimat
  • Exhibit 44: Combivent Sales 2011-2014 (US$ million)
  • Exhibit 45: Berodual Respimat Catridge and Parts of Berodual Respimat Inhaler
  • Exhibit 46: Ventolin HFA
  • Exhibit 47: Parts of Ventolin HFA
  • Exhibit 48: Sales of Ventolin 2011-2014 (US$ million)
  • Exhibit 49: Sales of Novartis's Pulmonary Delivery Drugs and Devices H1 2014 (US$ million)
  • Exhibit 50: Arcapta Neohaler
  • Exhibit 51: Seebri Breezhaler Capsules and Seebri Breezhaler Inhaler
  • Exhibit 52: Ultibro Breezhaler
  • Exhibit 53: Tobi Podhaler
  • Exhibit 54: Tobi Podhaler Blister Pack and Parts of Tobi Podhaler
  • Exhibit 55: SideStream Nebulizer
  • Exhibit 56: SideStream Plus
  • Exhibit 57: InnoSpire Deluxe
  • Exhibit 58: InnoSpire Elegance
  • Exhibit 59: InnoSpire Essence
  • Exhibit 60: I-neb AAD System
  • Exhibit 61: Parts of I-neb AAD System
  • Exhibit 62: Sami the Seal
  • Exhibit 63: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 64: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 65: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 66: Boehringer Ingelheim: Business Segmentation by Revenue 2013
  • Exhibit 67: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 68: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
  • Exhibit 69: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 70: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 71: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 72: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 73: Novartis AG: Business Segmentation
  • Exhibit 74: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 75: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 76: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 77: Philips Healthcare: Revenue by Business Segmentation 2012
  • Exhibit 78: Philips Healthcare: Sales by Geography 2012
Back to Top